Navigation Links
Study finds cancer-fighting goodness in cholesterol
Date:4/19/2012

A Simon Fraser University researcher is among four scientists who argue that cholesterol may slow or stop cancer cell growth. They describe how cholesterol-binding proteins called ORPs may control cell growth in A Detour for Yeast Oxysterol Binding Proteins, a paper published in the latest issue of the Journal of Biological Chemistry.

The scientists came to their conclusion while trying to understand how cholesterol moves around inside cells in the fat's journey to cell surfaces where it reinforces their outer membrane.

"The assumption was that ORPs bind and transport cholesterol inside cells in a similar fashion to how lipoproteins bind and move around the fat outside cells through the blood stream," explains Chris Beh. The SFU associate professor of molecular biology and biochemistry co-authored this paper.

Beh and his colleagues noted that genetic changes engineered by them block the ability of ORPs to bind cholesterol but don't stop ORPs from functioning. In fact, these altered ORPs work better and activate other regulator proteins, which in turn trigger a variety of cellular processes that stimulate cell growth.

The scientists believe this happened because cholesterol-binding normally interferes with ORPs' ability to bind to another lipid or fat called PI4P, which is important for cell growth.

"That told us that ORPs probably have nothing to do with moving around cholesterol within cells," says Beh. "Rather cholesterol-binding puts the brakes on ORP's ability to bind to PI4P which, if left unchecked, could accelerate cell growth like crazy," says Beh. "Given that uncontrolled cell growth is a key feature of cancer, this means gaining a better understanding of the true purpose of cholesterol-binding within cells could be important in cancer treatment."

Beh and his colleagues draw on two important facts to support their conclusion.

"First, cancer cells require ORPs to survive," explains Beh. "Second, other scientists have previously shown that a new class of natural compounds that look like steroids or cholesterol can kill a broad spectrum of different cancer cells."

Beh says he and his research partners will now find out exactly which proteins respond to ORP activation and under what circumstances does cholesterol turn off ORP's activation of them.


'/>"/>

Contact: Carol Thorbes
cthorbes@sfu.ca
778-782-3210
Simon Fraser University
Source:Eurekalert

Related biology news :

1. New study links air pollution and early death in the UK
2. Effect of chronic exposure to chemicals used as weapons, pesticides under study
3. NIST/UMass study finds evidence nanoparticles may increase plant DNA damage
4. Jellyfish on the rise: UBC study
5. Improved loblolly pines better for the environment, study finds
6. Study amplifies understanding of hearing in baleen whales
7. Large international study finds memory in adults impacted by versions of 4 genes
8. UF receives $1 million from Keck Foundation to study mechanisms of inherited disease
9. Whats in a surname? New study explores what the evolution of names reveals about China
10. U of I study: Lose body weight before gaining baby weight
11. Study resolves debate on human cell shut-down process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in a published evaluation of multiple immunoassay-based threat detection technologies by researchers ... Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have the ...
(Date:2/23/2017)... 23, 2017 Aviva Systems Biology Corporation ... acquisition of GenWay Biotech Incorporated, a protein solutions ... product offering for both the research and diagnostic ... and enhance capabilities for both entities. GenWay,s 18 years ... will nicely complement ASB,s objective to become a ...
Breaking Biology Technology: